Major therapeutic advances and new perspectives in onco-hematology;Avancées thérapeutiques majeures et nouvelles perspectives en onco-hématologie Major therapeutic advances and new perspectives in onco-hematology

Bulletin du Cancer

Volumn 100, Issue 6, 2013, Pages 587-599

  Bay, Jacques Olivier ^a,b   Guieze, Romain ^a,b   Ravinet, Aurélie ^a   Lemal, Richard ^a   Xhaard, Aliénor ^c   Bailly, Sébastien ^a   Molucon Chabrot, Cécile ^a   Hermet, Éric ^a   Biau, Julian ^d   Verrelle, Pierre ^d   De Latour, Régis Peffault ^c   Tournilhac, Olivier ^a,b  

^a UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d CENTRE JEAN PERRIN   (France)

Author keywords

Allograft; Cancer; Chemotherapy; Perspective; Retrospective; Targeted therapies

Indexed keywords

CANCER CHEMOTHERAPY; HEMATOLOGIC MALIGNANCY; HUMAN; REVIEW;

EID: 84880236590     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2013.1751     Document Type: Article

References (88)

1. Goodman LS, Wintrobe MM. Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. J Am Med Assoc 1946 ; 132 : 126-32.
2. Devita Jr. VT, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 1970 ; 73 : 881-95.
3. Rivers SL, Patno ME. Cyclophosphamide vs melphalan in treatment of plasma cell myeloma. JAMA 1969 ; 207 : 1328-34.
4. Alexanian R, Haut A, Khan AU, et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 1969 ; 208 : 1680-5.
5. Bernard J, Jacquillat C, Boiron M, et al. 57 cases of acute leukemia. Trial treatment with a semisynthetic daunorubicin derivative: 22,050 R.P. Nouv Presse Med 1972 ; 1 : 2149-52.
6. Bloomfield CD, Brunning RD, Kennedy BJ. Daunorubicin therapy in adult acute lymphatic leukemia. Cancer 1972 ; 30 : 47-55.
7. Jacquillat C, Boiron M, Weil M, et al. Rubidomycin. A new agent active in the treatment of acute lymphoblastic leukaemia. Lancet 1966 ; 2 : 27-8.
8. Bernard J,Weil M, Boiron M, et al. Acute promyelocytic leukemia: results of treatment by daunorubicin. Blood 1973 ; 41 : 489-96.
9. Döhner H, Estey EH, Amadori S, et al, European Leukemia- Net. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel. Blood 2010 ; 115 : 453-74.
10. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acutemyeloid leukemia. N Engl J Med 2009 ; 361 : 1249-59.
11. McKelvey EM, Gottlieb JA, Wilson HE, et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976 ; 38 : 1484-93.
12. Casper ES, Mittelman A, Kelson D, et al. Phase I clinical trial of fludarabine phosphate (F-ara-AMP). Cancer Chemother Pharmacol 1985 ; 15 : 233-5.
13. Badoux XC, Keating MJ, Wang X, et al. Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia. Blood 2011 ; 118 : 2085-93.
14. Keating MJ, O'Brien S, Kontoyiannis D, et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 2002 ; 43 : 1755-62.
15. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010 ; 376 : 1164-74.
16. Kurnick NB, Montano A, Gerdes JC, et al. Preliminary observations on the treatment of postirradiation hematopoietic depression in man by the infusion of stored autogenous bone marrow. Ann Intern Med 1958 ; 49 : 973-86.
17. Gorin NC, Najman A, Duhamel G. Autologous bonemarrow transplantation in acute myelocytic leukaemia. Lancet 1977 ; 1 : 1050.
18. Goodman JW, Hodgson GS. Evidence for stem cells in the peripheral blood of mice. Blood 1962 ; 19 : 702-14.
19. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981 ; 48 : 198-206.
20. Dighiero G, Maloum K, Desablens B, et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med 1998 ; 338 : 1506-14.
21. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the InternationalWorkshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008 ; 111 : 5446-56.
22. M'kacher R, Bennaceur-Griscelli A, Girinsky T, et al. Telomere shortening and associated chromosomal instability in peripheral blood lymphocytes of patients with Hodgkin's lymphoma prior to any treatment are predictive of second cancers. Int J Radiat Oncol Biol Phys 2007 ; 68 : 465-71.
23. Swerdlow AJ, Higgins CD, Smith P, et al. Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study. J Clin Oncol 2011 ; 29 : 4096-104.
24. Swerdlow AJ, Barber JA, Hudson GV, et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 2000 ; 18 : 498-509.
25. Fermé C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 2007 ; 357 : 1916-27.
26. Engert A, Franklin J, Eich HT, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol 2007 ; 25 : 3495-502.
27. Engert A, Schiller P, Josting A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with earlystage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003 ; 21 : 3601-8.
28. Bonadonna G, Zucali R, Monfardini S, et al. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975 ; 36 : 252-9.
29. Shahidi M, Kamangari N, Ashley S, et al. Site of relapse after chemotherapy alone for stage I and II Hodgkin's disease. Radiother Oncol 2006 ; 78 : 1-5.
30. Girinsky T, Van der Maazen R, Specht L, et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 2006 ; 79 : 270-7.
31. Campbell BA, Voss N, Pickles T, et al. Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size. J Clin Oncol 2008 ; 26 : 5170-4.
32. Engert A, Plütschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010 ; 363 : 640-52.
33. Straus DJ, Portlock CS, Qin J, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 2004 ; 104 : 3483-9.
34. Andre MP, Reman O, Federico M, et al. First Report On the H10 EORTC/GELA/IIL Randomized Intergroup Trial On Early FDGPET Scan Guided Treatment Adaptation Versus Standard Combined Modality Treatment in Patients with Supra-Diaphragmatic Stage I/II Hodgkin's Lymphoma, for the Groupe d'étude des lymphomes de l'adulte (GELA), European Organisation for the Research and Treatment of Cancer (EORTC) Lymphoma Group and the Intergruppo Italiano Linfomi (IIL). ASH Annual Meeting Abstracts 2009 ; 114 : 97.
35. Ganem G, Cartron G, Girinsky T, et al. Localized low-dose radiotherapy for follicular lymphoma: history, clinical results, mechanisms of action, and future outlooks. Int J Radiat Oncol Biol Phys 2010 ; 78 : 975-82.
36. Horning SJ,Weller E, Kim K, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 2004 ; 22 : 3032-8.
37. Reyes F, Lepage E, Ganem G, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 2005 ; 352 : 1197-205.
38. Yeoh K-W, Mikhaeel NG. Are we ready for positron emission tomography/computed tomography-based target volume definition in lymphoma radiation therapy? Int J Radiat Oncol Biol Phys 2013 ; 85 : 14-20.
39. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999 ; 340 : 1330-40.
40. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2- phenylaminopyrimidine derivative. Cancer Res 1996 ; 56 : 100-4.
41. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996 ; 2 : 561-6.
42. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001 ; 344 : 1031-7.
43. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002 ; 346 : 645-52.
44. Roy L, Guilhot J, Krahnke T, et al. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 2006 ; 108 : 1478-84.
45. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001 ; 293 : 876-80.
46. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010 ; 116 : 2040-5.
47. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011 ; 377 : 42-51.
48. Rowe JM, Löwenberg B. Gemtuzumab ozogamicin in acutemyeloid leukemia: a remarkable saga about an active drug. Blood 2013.
49. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010 ; 363 : 1812-21.
50. Bernard J, Mathe G, Boulay J, et al. Acute promyelocytic leukemia: a study made on 20 cases. Schweiz Med Wochenschr 1959 ; 89 : 604-8.
51. Wang F, Travins J, Delabarre B, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 2013.
52. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009 ; 10 : 223-32.
53. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005 ; 352 : 2487-98.
54. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999 ; 341 : 1565-71.
55. Jacobson LO, Marks EK, Robson MJ, Gaston EO, Zirkle RE. The effect of spleen protection on mortality following X-irradiation. J Lab Clin Med 1949 : 1538-43.
56. Barnes DW, Corp MJ, Loutit JF, et al. Treatment of murine leukaemia with X rays and homologous bone marrow; preliminary communication. Br Med J 1956 ; 2 : 626-7.
57. Thomas ED, Lochte Jr. HL, Cannon JH, et al. Supralethal whole body irradiation and isologous marrow transplantation in man. J Clin Invest 1959 ; 38 : 1709-16.
58. Mathé G, Amiel JL, Schwarzenberg L, et al. Adoptive immunotherapy of acute leukemia: experimental and clinical results. Cancer Res 1965 ; 25 : 1525-31.
59. Gatti RA, Meuwissen HJ, Allen HD, et al. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 1968 ; 2 : 1366-9.
60. Dausset J. Iso-leuko-antibodies. Acta Haematol 1958 ; 20 : 156- 66.
61. Storb R, Yu C, Wagner JL, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997 ; 89 : 3048-54.
62. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998 ; 91 : 756-63.
63. Koh LP, Chao N. Haploidentical hematopoietic cell transplantation. Bone Marrow Transplant 2008 ; 42 : S60-3.
64. Gluckman E, Broxmeyer HA, Auerbach AD, et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med 1989 ; 321 : 1174-8.
65. Andrews PL, Rapeport WG, Sanger GJ. Neuropharmacology of emesis induced by anti-cancer therapy. Trends Pharmacol Sci 1988 ; 9 : 334-41.
66. Marty M, The Granisetron Study Group. A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. Eur J Cancer 1990 ; 26 : S28-32.
67. Rizk AN, Hesketh PJ. Antiemetics for cancer chemotherapyinduced nausea and vomiting. A review of agents in development. Drugs R D 1999 ; 2 : 229-35.
68. Dos Santos LV, Souza FH, Brunetto AT, et al. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review. J Natl Cancer Inst 2012 ; 104 : 1280-92.
69. Gratwohl A, Brand R, Frassoni F, et al. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone MarrowTransplant 2005 ; 36 : 757-69.
70. Beyer J, Schwartz S, Heinemann V, et al. Strategies in prevention of invasive pulmonary aspergillosis in immunosuppressed or neutropenic patients. Antimicrob Agents Chemother 1994 ; 38 : 911-7.
71. Tattersall MH, Spiers AS, Darrell JH. Initial therapy with combination of five antibiotics in febrile patients with leukaemia and neutropenia. Lancet 1972 ; 1 : 162-5.
72. Paul M, Shani V, Muchtar E, et al. Systematic review and metaanalysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother 2010 ; 54 : 4851-63.
73. Tancrède CH, Andremont AO. Bacterial translocation and gramnegative bacteremia in patients with hematological malignancies. J Infect Dis 1985 ; 152 : 99-103.
74. Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005 ; 353 : 977-87.
75. Nivoix Y, Velten M, Letscher-Bru V, et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 2008 ; 47 : 1176-84.
76. Segal BH. Aspergillosis. N Engl J Med 2009 ; 360 : 1870-84.
77. Van Burik J-AH, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004 ; 39 : 1407-16.
78. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007 ; 356 : 348-59.
79. Konopleva MY, Jordan CT. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol 2011 ; 29 : 591-9.
80. Uy GL, Rettig MP, Motabi IH, et al. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood 2012 ; 119 : 3917-24.
81. Ramsay AG, Clear AJ, Fatah R, et al. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood 2012 ; 120 : 1412-21.
82. Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012 ; 481 : 506-10.
83. Landau DA, Carter SL, Stojanov P, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013 ; 152 : 714-26.
84. Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012 ; 150 : 264-78.
85. Shi H, Liu L, Wang Z. Improving the efficacy and safety of engineered T cell therapy for cancer. Cancer Lett 2013 ; 328 : 191-7.
86. Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptormodified T cells in chronic lymphoid leukemia. N Engl J Med 2011 ; 365 : 725-33.
87. Schuster SJ, Neelapu SS, Gause BL, et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol 2011 ; 29 : 2787-94.
88. Van Brussel I, Berneman ZN, Cools N. Optimizing dendritic cell-based immunotherapy: tackling the complexity of different arms of the immune system. Mediators Inflamm 2012 ; 2012 : 690643.